Journal
SLAS DISCOVERY
Volume 26, Issue 4, Pages 474-483Publisher
ELSEVIER SCIENCE INC
DOI: 10.1177/2472555220979584
Keywords
targeted degradation; pharmacology; ligand binding; receptor binding; medicinal chemistry; cell-based assays; biomarkers
Funding
- Deerfield
Ask authors/readers for more resources
Proteolysis targeting chimeras (PROTACs) are emerging as a promising strategy for targeted protein degradation in drug discovery. However, challenges such as complex physicochemistry and the development of orally bioavailable drugs need to be addressed for PROTACs to reach their full potential.
Proteolysis targeting chimeras (PROTACs) are heterobifunctional compounds that recruit the E3 ubiquitin ligase machinery to proteins of interest, resulting in their ubiquitination and subsequent proteasomal degradation. Targeted protein degradation has generated considerable interest in drug discovery because inhibition of one particular function of a protein often does not deliver the therapeutic efficacy that results from whole-protein depletion. However, the physicochemistry and intrinsically complex pharmacology of PROTACs present challenges, particularly for the development of orally bioavailable drugs. Here we describe the application of a translational pharmacology framework (called the four pillars) to expedite PROTAC development by informing pharmacokinetic-pharmacodynamic (PKPD) understanding and helping elucidate structure-activity relationships. Experimental methods are reviewed that help illuminate exposure of the drug or probe at the site of action (pillar 1) and engagement of its target(s) (pillar 2) that drive functional pharmacological effects (pillar 3) resulting in modulation of a relevant phenotype (pillar 4). We hope the guidance will be useful to those developing targeted protein degraders and help establish PROTAC molecules as robust target validation chemical probes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available